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Abstract
Tuberous sclerosis complex (TSC) is a genetic disorder characterised by highly variable comorbid dysfunction and
subsequent morbidity. The mTOR inhibitor everolimus is indicated for the treatment of adult TSC patients with
renal angiomyolipomas (AMLs) and for subependymal giant astrocytoma (SEGA) in both adults and children, based
on data from the EXIST-1 and EXIST-2 trials. However, due to the historical predominance of everolimus in the
oncology setting, some physicians who treat TSC patients may be unfamiliar with everolimus-associated adverse
events (AEs) and appropriate management strategies. This article aims to serve as a resource for specialists
including nephrologists, paediatricians, neurologists and geneticists who require practical guidance on the
management of events such as non-infectious pneumonitis, rash, stomatitis, infections, and renal AEs. Additional
consideration is given to drug interactions, hepatic impairment, fertility, and sexual maturation. Since patients with
TSC receive clinical benefit from continued therapy, it is important that everolimus-related events are dealt with
appropriately through strategies such as dose modification, interruption, the provision of supportive care, regular
monitoring, and patient education.
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Background
Tuberous sclerosis complex
Tuberous sclerosis complex (TSC) is an autosomal dom-
inant genetic disorder [1]. Prevalence rates vary, but esti-
mates typically fall in the range of 6.8 to 12.4 per
100,000 people [2]. TSC is caused by mutations in TSC1
on chromosome 9 or TSC2 on chromosome 16; how-
ever, two-thirds of cases result from de novo mutations
[3]. Mutations in TSC1 or TSC2 result in inappropriate
mTORC1 signalling within cells, and this is thought to
be responsible for many of the features of TSC [4].
TSC is a highly variable condition in both the type and
severity of its manifestations. A history of seizures has
been reported in up to 85% of patients, often beginning
in the first few years of life (>80% of patients) [5–7],
with intellectual disability found in ~45% of cases [8].
The condition is also commonly associated with the
development of benign tumours in organs such as the
kidneys, brain, heart and skin [9, 10]. Renal angio-
myolipomas (AMLs) are among the most common
features of TSC [9, 10], affecting around ~70% of pa-
tients [11, 12]. They manifest as benign tumours
composed of abnormal blood vessels and cells, with
either adipocyte-like or smooth muscle-like pheno-
types [9], and commonly occur in both kidneys [9].
Around 20% of patients with TSC develop subependy-
mal giant astrocytoma (SEGA), a benign glioneuronal
brain tumour [13], and ~10% of women with TSC de-
velop symptomatic lymphangioleiomyomatosis (LAM),
a condition characterised by cystic destruction of the
lung, pneumothorax and chylous pleural effusion [1].
This comorbid organ dysfunction and associated dis-
ease burden [10] requires careful management. The
care of people with TSC can therefore be complex
and requires a multidisciplinary approach [14].
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Treating TSC
Normalisation of defective mTORC1 signalling may be
an effective approach to managing patients with TSC.
Several mTORC1 inhibitors are in clinical use for many
conditions and have the potential as therapeutic agents
in TSC. Clinical trials have demonstrated the efficacy of
some of these agents in the treatment of TSC. The
mTOR inhibitor sirolimus has shown efficacy in clinical
trials investigating the treatment of patients with AML
and LAM [15–18], while another mTOR inhibitor,
everolimus, is indicated for the treatment of adult pa-
tients with renal AML associated with TSC who are at
risk of complications (based on factors such as tumour
size or presence of aneurysm, or presence of multiple or
bilateral tumours), but who do not require immediate
surgery; and of patients with SEGA who require thera-
peutic intervention, but who are not amenable to sur-
gery [19]. Three randomised, placebo-controlled phase
III trials have demonstrated the efficacy and safety of
everolimus in these patients [20–22].
EXIST-1 assessed the efficacy and tolerability of evero-
limus 4.5 mg/m2/day compared with placebo in 117 pa-
tients with a SEGA of ≥1 cm in diameter, and showed
that response rate (reduction in the total volume of all
target SEGA of 50% or more relative to baseline, in the
absence of worsening of non-target SEGA, new lesions
of 1 cm or greater in diameter, and new or worsening
hydrocephalus) was greater in everolimus- than placebo-
treated patients (35% versus 0%; p < 0.0001) [21]. At a
median follow-up of 9.7 months, 97% of patients in the
everolimus group were undergoing treatment; further-
more, no everolimus-treated patients discontinued due
to disease progression. In an open-label extension phase
of EXIST-1, responses persisted in 94% of responders,
and only 8% of all patients had SEGA progression at a
median follow-up of 28.3 months [23]. EXIST-2 com-
pared oral everolimus 10 mg/day with placebo in 118
adults with TSC and at least one AML of ≥3 cm in
diameter [20]. In this study, 42% of everolimus- and 0%
of placebo-treated patients (p < 0.0001) had a confirmed
AML response (reduction in AML volume [sum of vol-
umes of all target AMLs identified at baseline] of ≥50%
or more relative to baseline and absence of AML pro-
gression), with a median time to response of 2.9 months
in the everolimus group [20]. Long-term follow up (me-
dian 28.9 months) showed an increase in response rate
to 54%, with 97% of patients experiencing a reduction in
tumour volume [24]. The final four-year analysis of 112
patients, including those who had crossed over from pla-
cebo, showed an overall response rate of 58% after a me-
dian duration of everolimus exposure of 204.1 weeks
[19]. Recent data from the phase III EXIST-3 showed
that adjunctive everolimus in patients receiving one to
three antiepileptic drugs significantly reduced the rate of
seizures in TSC patients refractory to treatment (29.3%
and 39.6% reduction in seizure rate for 3–7 ng/mL
and 9–15 ng/mL trough concentrations vs a 14.9% re-
duction with placebo), and increased the response
rate (defined as ≥50% reduction; 28.2% and 40%, vs
15.1% for placebo) [22].
Safety of everolimus
The tolerability of everolimus in the EXIST studies was
similar to that for other indications such as renal cell
carcinoma, breast cancer, and transplantation [25–28].
In EXIST-1, 96 and 90% of everolimus- and placebo-
treated patients, respectively, experienced AEs [21].
Common adverse events (AEs) seen in EXIST-1 and -2
are listed in Table 1 [20, 21]. In both studies, the major-
ity of AEs were grade 1–2 in severity [21, 24], although
in EXIST-1 grade 3–4 AEs were reported in 33 and 23%
of patients in the everolimus and placebo groups, re-
spectively, with stomatitis, pyrexia and convulsion being
the most common such events [21]. A total of 2 grade 4
events occurred in EXIST-1 (gastroenteritis and hyper-
uricaemia) and 4 occurred in EXIST-2 (raised blood uric
acid, neutropenia, seizure and hypertension); no patients
died in EXIST-1 while one patient in EXIST-2 died from
status epilepticus not related to treatment [20, 21].
Female fertility-related AEs were a common finding in
the EXIST-1 and -2 trials. In a pooled analysis of the
data from these two studies (as well as a single-arm
phase II study), the most common of such events
were amenorrhoea (24.1%) and irregular menstruation
(17.0%); the majority of amenorrhoea events were
grade 1 or 2 in severity and resolved without inter-
vention [29]. 6.3% of patients experienced grade 3
amenorrhoea. Everolimus had no effect on the timing
of menarche in patients attaining menarche during
the treatment period [29].
During long-term follow-up of EXIST-1, there were no
differences in standard deviation scores for growth vari-
ables (height, height velocity, weight and weight velocity)
in patients aged <18 years before and during treatment
[23]; in the long-term follow-up of EXIST-2, glomerular
filtration rate (GFR) remained stable [24], renal AEs oc-
curred less frequently with everolimus than placebo [24],
and no patients experienced angiomyolipoma-related
bleeding [30]. In EXIST-3, everolimus exhibited a similar
AE profile, with the most frequently reported events be-
ing stomatitis, diarrhoea, mouth ulceration, nasopharyn-
gitis, upper respiratory tract infection, aphthous ulcer
and pyrexia. Discontinuations due to AEs were low [22].
Everolimus dosing
Everolimus is available as either tablets or dispersible
tablets, the availability of which differs from country to
country. For patients with TSC who are unable to
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swallow tablets, the tablets can be completely dissolved
in a glass containing ~30 mL of water through gentle
stirring for approximately 7 min, immediately prior to
drinking. Any remaining residue after drinking must be
re-dispersed in ~30 mL of water and swallowed. Dis-
persible tablets dissolve in water more quickly than
standard tablets.
Doses that are effective and well-tolerated vary be-
tween patients. Therefore, in order to obtain the optimal
therapeutic effect, careful dose titration may be required.
Treatment should also continue for as long as patients
receive a clinical benefit, or until the case of unaccept-
able toxicity.
The recommended starting dose of everolimus in adult
TSC patients with renal AML is oral 10 mg/day, and
was used in the EXIST-2 and oncology studies, selected
in order to maximise the probability of observing a
therapeutic effect. Dose reductions and/or temporary
interruption may be required in some patients who ex-
perience treatment-related AEs [19]; however evidence
suggests that this may not impact therapeutic effect.
There was no correlation between absolute change from
baseline in blood concentration and the therapeutic ef-
fect in EXIST-2, other than patients with the highest
trough concentrations having faster initial AML shrink-
age [31], and despite the fact that a third of patients re-
ceived dose reductions to 5 mg or 2.5 mg daily almost
all patients who remained on everolimus experienced
sustained and progressive AML shrinkage [24]. Hence,
in clinical practice, many clinicians may use a starting
dose of 5 mg in renal AML and titrate up or down ac-
cording to therapeutic response and AEs. The dose can
be titrated to achieve a trough concentration of 5–
15 ng/mL; however, responses have been seen at trough
concentrations as low as 3 ng/mL [20], so dose increases
may not be necessary once acceptable efficacy has been
achieved. Response of renal AML should be assessed
after approximately 12 weeks of therapy by imaging of
the kidneys. How frequently subsequent scans should be
carried out is unclear. For patients who have been
established on everolimus for some time and who are
clinically stable, performing a scan at least annually is
reasonable [14].
For SEGA, the dosing of everolimus should be indivi-
dualised according to body surface area (BSA) using the
Dubois formula, based on weight (W; in kg) and height
(H; in cm) [19]:
BSA ¼ W0:425  H0:725  0:007184
The recommended starting dose in SEGA is 4.5 mg/
m2/day. A higher starting dose of 7 mg/m2/day could be
considered for patients aged 1 year to <3 years. SEGA
volume should be evaluated approximately 3 months
after commencing everolimus, with subsequent dose
adjustments due to changes in SEGA volume, corre-
sponding trough concentration, and tolerability taken
into consideration.
Everolimus is not licensed for the treatment of chil-
dren with TSC-associated AMLs, but there is evidence
of its effectiveness [32] and it is funded by NHS England
[33]. If everolimus is used for non-licensed indications
in children then the recommended dose to treat these
cases can be drawn from the treatment of SEGA, where
the recommended starting dose for children aged
≥3 years is 4.5 mg/m2/day. Everolimus is licensed and
used worldwide for SEGA not amenable to surgery in
both children and adults.
Table 1 The most common adverse events (>10%) in SEGA
patients aged 0–65 years in EXIST-1 and adult AML patients in
EXIST-2 [20, 21]
Adverse event (all grades) EXIST-1 EXIST-2
Everolimus
4.5 mg/m2
per day
Placebo Everolimus
10 mg/day
Placebo
Mouth ulceration 32 5 16 5
Stomatitis 31 21 48 8
Convulsion 23 26 - -
Pyrexia 22 15 - -
Nasopharyngitis 18 23 24 31
Vomiting 17 13 15 5
Upper respiratory tract infection 15 18 10 5
Fatigue 14 3 18 18
Cough 13 10 20 13
Diarrhoea 13 5 13 5
Rash 12 5 - -
Bronchitis 10 10 - -
Otitis media 10 5 - -
Pharyngitis 10 3 - -
Acne-like skin lesions - - 22 5
Headache - - 22 18
Hypercholesterolaemia - - 20 3
Aphthous stomatitis - - 19 10
Nausea - - 16 13
Urinary tract infection - - 15 15
Anaemia - - 13 3
Arthralgia - - 13 5
Abdominal pain - - 11 8
Blood lactate dehydrogenase
increased
- - 11 5
Hypophosphataemia - - 11 0
Eczema - - 10 8
Leucopenia - - 10 8
Oropharyngeal pain - - 10 10
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TSC treatment: current challenges
There are a number of important challenges relating to
everolimus use for the treatment of TSC. In particular,
although everolimus is indicated for TSC-related AML
and SEGA, the majority of experience with the drug
comes from oncological indications. Furthermore, there
is no clear and defined management pathway for TSC
and patients may be seen by any number of different
specialists depending on their presentation. In addition,
many healthcare professionals who treat TSC are un-
familiar with everolimus and are unsure about prescrib-
ing it to their patients. AEs may be of particular
concern; however, their successful management will in-
crease the number of patients who can tolerate everoli-
mus long-term and, therefore, help to optimise
treatment benefit, which will help ensure sustained effi-
cacy and adherence.
The aim of this article is to provide practical guidance
to nephrologists and other specialists such as paediatri-
cians, neurologists and geneticists who treat patients
with TSC, including providing advice on what to con-
sider at a patient’s first consultation and the key investi-
gations to perform. Guidance will also be provided on
the management of AEs, including lessons from everoli-
mus use in oncological indications, as well as recom-
mendations for patient education.
Initiating everolimus in patients with TSC
Patients with TSC require special considerations prior to
the initiation of everolimus treatment (Fig. 1). Before
treatment is given, a full blood count and liver and kid-
ney function tests should be performed. Serum electro-
lytes and creatinine should be measured, and urine
protein estimated by dipstick analysis and protein:creati-
nine ratio. Baseline lipids should be measured; if fasting
lipids cannot be ascertained then random cholesterol is
an acceptable substitute. If lipids are significantly ele-
vated then improved lipid control should ideally be ob-
tained before starting everolimus (e.g. through dietary
modifications or statins).
Fasting blood glucose should also be measured, but in
the absence of this a random glucose and glycated
haemoglobin test can be performed. If these tests are ab-
normal, optimal glycaemic control should be achieved
before starting everolimus whenever possible.
Because mTOR inhibitors have immunosuppressive
properties, a thorough medical history relating to infec-
tion should also be obtained (e.g. history of pneumonia,
recurrent otitis media, sinusitis, fungal infections, hepa-
titis, HIV, tuberculosis) [34]. A hepatitis screen may be
warranted due to the potential risk of virus reactivation.
Patients with respiratory symptoms or radiological evi-
dence suggestive of LAM should have a computed tom-
ography scan, lung function tests, transfer factor of the
lung for carbon monoxide and arterial oxygen saturation
before everolimus administration.
Patients should be provided with information and ad-
vice on how their treatment may impact their daily life.
It may be beneficial to pre-emptively prescribe or rec-
ommend items such as non-alcoholic mouthwashes and
soft toothbrushes before the occurrence of AEs such as
stomatitis. Another important consideration before pre-
scribing treatment is to take an inventory of current
medications patients are receiving; information on
drug–drug interactions is presented later in this article.
Live vaccines should be avoided or completed before
initiating everolimus owing to its immunosuppressive
properties. Treatment with everolimus should be delayed
or temporarily discontinued in patients undergoing sur-
gery because the drug can delay wound healing [34]. Fi-
nally, as everolimus tablets contain lactose, patients with
rare hereditary problems of galactose intolerance, Lapp
lactase deficiency or glucose–galactose malabsorption
should not take the drug [19].
Paediatric considerations
Understandably, clinicians have concerns regarding the
use of mTOR inhibitors in children, specifically regard-
ing their effect on growth and gonadal function over the
long-term. There are few studies that have evaluated the
use of mTOR inhibitors in children with TSC [35, 36],
however 5-year data from a phase II study show that
growth parameters such as height, height velocity and
weight in children were comparable before and after
starting treatment [36]. Furthermore, paediatric kidney
transplant studies with mTOR inhibitor-treated patients
suggest no effect on longitudinal growth as well as com-
parable ages of sexual maturation and reproductive hor-
mone levels when compared with kidney transplant
patients who did not receive mTOR inhibitors [37–40].
Some studies of sirolimus have suggested the occurrence
of testosterone suppression in adolescents [41] and
adults [42–44], however most of these studies had small
numbers of patients and used a higher dose regimen
compared to recent studies.
Standard recommendation currently advises against
concomitant use of everolimus on ketogenic diets in
children with epilepsy, which is due to additive toxicity
with hyperlipidaemia. Although data are limited regard-
ing this side effect, the authors would recommend that
clinicians use their discretion while prescribing mTOR
inhibitors in such cases.
Managing adverse events
Common AEs associated with the use of everolimus in
TSC are stomatitis, nasopharyngitis, acne-like skin le-
sions, headache, cough and hypercholesterolaemia.
Other AEs occurring in ≥10% of patients in the EXIST-1
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Fig. 1 Protocol for initiation and monitoring of everolimus therapy. *≤1.2 m2 = 2.5 mg once daily, 1.3–2.1 m2 = 5 mg once daily, ≥2.2 m2 = 7.5 mg
once daily; †In the event of bleeding, temporary cessation of everolimus may be required for embolisation; everolimus may be restarted following
healing if needed to control AML growth. AML angiomyolipoma, BSA body surface area, GFR glomerular filtration rate, GP general practitioner, SEGA
subependymal giant astrocytoma
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and -2 trials are shown in Table 1 [20, 21]; the Common
Terminology Criteria for Adverse Events (CTCAE) are
shown in Table 2 [45].
The management of AEs may require dose reduction
or temporary cessation of therapy (Table 3) [19]. As a
general rule, this should be considered with all grade 2–
3 AEs thought to be everolimus treatment-related; adjust-
ments are usually not required for grade 1 AEs. When a
dose reduction is needed, it is recommended that the new
dose should be around 50% lower than that previously ad-
ministered. For dose reduction below the lowest available
strength, alternate day dosing should be considered. If the
AE is persistent or recurrent, the dose should be inter-
rupted for 3–14 days (or until the AE is resolved to grade
≤1), with everolimus then restarted at a lower dose. Dose
interruption/reduction can help to ameliorate AEs while
allowing for continued therapeutic benefit, as evidenced
in EXIST-2 in which 71% of patients had a dose interrup-
tion/reduction and around a third were maintained on
doses less than the initial 10 mg/day [24].
Many patients with TSC have learning difficulties and
may not be reliably able to report any toxicities, or the
toxicities may manifest in atypical ways such as altered
behaviour, e.g. pain can manifest as increased aggression,
withdrawal or sleep disturbance. Family members and
other carers are often attuned to such changes, and any
concerns they raise must be taken seriously.
Based on lessons from clinical trials in TSC-related
conditions and oncology indications, and from our own
clinical experience, we have provided the following guide
as a reference for nephrologists and other specialists
who may encounter specific AEs in their patients. AEs
of note have been listed, along with a summary of their
presentation, practical advice for physicians and import-
ant information that should be communicated to pa-
tients to aid in their management.
Non-infectious pneumonitis
Non-infectious pneumonitis is a class effect of rapamy-
cin analogues, such as everolimus and temsirolimus. A
Table 2 Grading of key everolimus-related adverse events based on National Cancer Institute Common Terminology Criteria for
Adverse Events (CTCAE) [45]
Adverse event Grade 1 Grade 2 Grade 3 Grade 4
Non-infectious pneumonitis Asymptomatic Symptomatic; not interfering
with ADL
Severe symptoms; interfering
with ADL, oxygen indicated
Life-threatening respiratory
comprise; urgent
intervention indicated
Infections None Localised; local intervention
indicated
IV antibiotic, antifungal or
antiviral intervention
indicated; radiology/operative
intervention indicated
Life-threatening
consequences, e.g. septic
shock, hypotension,
acidosis, necrosis
Stomatitis Minimal; normal diet Symptomatic, but can eat
and swallow; modified diet
Symptomatic; unable to
adequately aliment or
hydrate orally
Symptoms associated
with life-threatening
consequences
Rash Macular or popular eruption
or erythema without
associated symptoms
Macular or papular eruption
or erythema with pruritus
or other associated
symptoms; localised
desquamation or other
lesions covering
Severe, generalised
erythroderma or macular,
papular or vesicular eruption;
desquamation covering
≥50% BSA
Generalised exfoliative,
ulcerative, or bullous
dermatitis
Metabolic events
Hypercholesterolaemia, >ULN–300 >300–400 >400–500 >500
mg/dL (mmol/L) (>ULN–7.75) (>7.75–10.34) (>10.34–12.92) (>12.92)
Hyperglycaemia, >ULN–160 >160–250 >250–500 >500
mg/dL (mmol/L) (>ULN–8.9) (>8.9–13.9) (>13.9–27.8) (>27.8 or acidosis)
Hypophosphataemia, <LLN–2.5 <2.5–2.0 <2.0–1.0 <1.0
mg/dL (mmol/L) (<LLN–0.8) (<0.8–0.6) (<0.6–0.3) (<0.3)
Hypertriglyceridaemia >ULN–2.5 × ULN >2.5–5.0 × ULN >5.0–10.0 × ULN >10.0 × ULN
- - - -
Hyperiuricaemia, mg/dL (mmol/L) >ULN–10 (≤0.59 without
physiologic consequences)
- >ULN–10 (≤0.59 without
physiologic consequences)
>10 (>0.59)
Myelosuppression, 109/L
Platelets <LLN–75.0 <75.0–50.0 <50.0–25.0 <25.0
Neutrophils <LLN–1.5 <1.5–1 <1.0–0.5 <0.5
ADL activities of daily life, BSA body surface area, IV intravenous, LLN lower limit of normal, ULN upper limit of normal
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diagnosis of non-infectious pneumonitis should be
considered in patients with TSC presenting with new
or worsening signs, or with non-specific respiratory
symptoms such as cough or dyspnoea, the develop-
ment of a pleural effusion, or radiological changes
(ground-glass opacities and focal consolidation, pre-
dominantly in the lower lobes). Pneumonitis grading
is shown in Table 2.
Recommendations for dose modification in everolimus-
treated patients experiencing non-infectious pneumonitis
are provided in Table 3. Differentiating non-infectious
pneumonitis from infection is a key issue for investiga-
tions. Pneumocystis jiroveci pneumonia and Legionella
should be ruled out.
Treatment interruption, dose reductions and treat-
ment with corticosteroids (e.g. in adults, 3–7 days of
30–60 mg prednisolone followed by steroid tapering)
and antibiotics are the common management strategies
for non-infectious pneumonitis. It is important to try
and exclude an infectious aetiology before the use of
corticosteroids. Early proactive management is a must,
and dose reduction should be considered as early as
grade 1. Patients who develop radiological changes sug-
gestive of non-infectious pneumonitis and those have
few or no symptoms may continue everolimus without
dose adjustments.
Patients should be advised to report promptly any
new or worsening respiratory symptoms, and it is
Table 3 Dose modification recommendations for key everolimus-related adverse events
Adverse event Grade 1 Grade 2 Grade 3 Grade 4
Non-infectious pneumonitis [19] Consider a 50%
decrease in
everolimus dose
Consider interruption of therapy
until symptoms improve to
grade ≤1; re-initiate at 50% of
previous dose. Discontinue if
no recovery within 4 weeks
Interrupt everolimus until symptoms
resolve to grade ≤1; consider
re-initiating at 50% of previous dose.
If toxicity recurs at grade 3, consider
discontinuation
Discontinue everolimus
Infectionsa No change in
everolimus dose
Maintain dose if tolerated;
interrupt if intolerable or
grade 2 recurrence until
recovery to grade ≤1 then
restart at same dose.
Interrupt dose until recovery to
grade ≤1, then restart at reduced
dose. If dose interrupted >21 days,
consider discontinuation
Discontinue everolimus
Stomatitis [19] - Temporary dose interruption
until recovery to grade ≤1;
re-initiate at same dose. If AE
recurs at grade 2, interrupt
dose until recovery to
grade ≤1; re-initiate at 50%
of previous dose
Temporary dose interruption until
recovery to grade ≤1; re-initiate at
50% of previous dose
Discontinue everolimus
Rasha - If toxicity tolerable, no dose
adjustment required. If
intolerable, temporary dose
interruption until recovery to
grade ≤1; re-initiate at same
dose. If AE recurs at grade 2,
interrupt dose until recovery
to grade ≤1; re-initiate at 50%
of previous dose
Temporary dose interruption until
recovery to grade ≤1. Consider
re-initiating at 50% of previous dose.
If toxicity recurs at grade 3, consider
discontinuation
Metabolic events [19]
Hypercholesterolaemia
Hyperglycaemia
Hypophosphataemia
Hypertriglyceridaemia
Hyperiuricaemia
- No dose adjustment required Temporary dose interruption;
reinitiate at 50% of previous dose
Discontinue everolimus
Myelosuppression [19]
Platelets
Neutrophils
Temporary dose interruption
until recovery to grade ≤1;
reinitiate at same dose
No dose adjustment required
Temporary dose interruption until
recovery to grade ≤1; reinitiate at
50% of previous dose
Temporary dose interruption until
recovery to grade ≤2; reinitiate
at same dose
Temporary dose interruption
until recovery to grade ≤1;
reinitiate at 50% of previous
dose
Temporary dose interruption
until recovery to grade ≤2;
reinitiate at 50% of previous
dose
Febrile neutropenia [19] - - Temporary dose interruption until
recovery to grade ≤2 (≥1.25 × 109/L)
and no fever; reinitiate at
approximately 50% of previous dose
Discontinue everolimus
AE adverse event
aAuthor recommendation
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recommended that patients keep a diary to monitor
these effects [19]. In addition, patients may consider
taking warm baths/showers, or using a vaporiser to
help thin out secretions; and avoiding allergens, such
as smoke and pollen, if pneumonitis is present [46].
Infections
While the rates of infections were no higher with evero-
limus than placebo in the EXIST-1 and -2 studies
(around 70% in both groups in both trials) [20, 21],
everolimus has immunosuppressive properties and pa-
tients may be susceptible to bacterial, fungal, viral or
protozoal infections, including opportunistic pathogens
and reactivation of previous infections (see Table 1 for a
list of described infections). Hence, in normal clinical
practice some increase in infection rates may be ex-
pected, even in patients not taking other concurrent im-
munosuppressants. Any pre-existing infections should
be treated appropriately and resolved before commen-
cing therapy. Guidelines for hepatitis B screening,
prophylaxis and reactivation management have been de-
veloped [34].
If a diagnosis of infection is made, appropriate treat-
ment must be given promptly. Everolimus interruption/
discontinuation should also be considered in this sce-
nario, particularly when associated with fever. In cases
of invasive systemic fungal infection, everolimus should
be discontinued and appropriate antifungal therapy initi-
ated [34]. Patients being treated with everolimus should
be warned about the risk of infection and educated on
the need to seek medical help if they develop suggestive
symptoms and if they develop cuts or wounds because
these are at an elevated risk of becoming infected. Fur-
thermore, to reduce the risk of infection, patients should
wash their hands frequently keep food preparation areas
clean, and avoid cleaning up after pets.
Stomatitis
Stomatitis is an inflammation of the mucous membranes
in the oral cavity, inner surface of the lips or the tongue,
and is associated with erythema, oedema, a burning sen-
sation and occasionally bleeding. It can impair a patient’s
ability to eat, swallow and talk, and can cause significant
pain. Stomatitis is one of the most common AEs in pa-
tients treated with mTOR inhibitors, although the effect
is typically transient. It usually occurs within 1 month of
treatment initiation.
The early and active management of stomatitis is es-
sential. When starting everolimus, patients should be is-
sued with suitable oral care products (e.g. sucralfate
suspension, bioadherent oral rinse gels, raspberry muci-
lage). For example, sucralfate suspension can be applied
3–4 times day with a cotton wool bud to the ulcer or pa-
tients can rinse and spit. The sucralfate suspension can
also be swallowed if the patient has a lesion in the phar-
ynx. The steroid triamcinolone acetonide can be used
for ulcers on or inside the lip, or in the front of the
mouth [34]. For those who do not respond to these
medications, or those who require greater pain control,
a topical analgesic (e.g. benzocaine with or without a
steroid) may be required. Some clinicians recommend a
‘magic mouthwash’ for which several formulations are
available, but which typically contains a topical anaes-
thetic, a steroid, an antibiotic, an anti-fungal and an
antacid – it should however be noted that concomitant
anti-fungals are not recommended with everolimus
treatment [19]. Direct application of clobetasol, a high
potency steroid, has been associated with rapid symp-
tomatic improvement in mTOR-treated patients with
aphthous ulceration [47].
All patients with stomatitis should receive recommen-
dations regarding good oral care. This may include con-
sistent regular brushing with a soft toothbrush that is
changed on a regular basis, frequent rinsing with bland
rinses (e.g. sterile water, saline or sodium bicarbonate),
and avoidance of strong-flavoured toothpastes and those
containing lauryl sulphate; instead, children’s toothpastes
may be favoured. Mouthwashes containing alcohol
should be avoided. Patients should also avoid acidic,
spicy, hard or crunchy foods, those that are too hot in
temperature, and alcohol. Care should be taken when
eating and drinking; it may be advisable to eat 5–6
smaller meals per day and drink through a straw. Physi-
cians should also consider vitamin B and zinc supple-
mentation prior to everolimus initiation; while the data
supporting the evidence of this in ameliorating mouth
ulcers are mixed [48–51], there are likely patients who
are both deficient and predisposed to this side effect of
mTOR inhibition and who would therefore benefit.
Rash
Rash in everolimus-treated patients is usually macular or
papular, and may also contain pustules and eczematous
changes. It is most commonly found on the face, upper
trunk and scalp, and may be associated with pruritus.
Topical treatments are typically the first choice for man-
aging rash, such as those products containing benzoyl
peroxide and an antibiotic, or topical steroids, such as
alcometasone or mometasone.
Oral antibiotics (e.g. minocycline or doxycycline) may
also be necessary. In patients with pruritus, topical
emollients or antihistamines may be advisable. Retinoids
should be avoided as they may disrupt skin integrity and
potentially increase risk of infection. Physicians should
advise patients to consider the following advice: wear
loose, comfortable clothing; use mild soaps without per-
fume and take short, lukewarm showers; when washing
and drying, pat the area instead of rubbing with a towel
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or washcloth; avoid tanning booths; use a moisturiser
frequently; and use sunscreen (at least SPF 15) [52].
Metabolic events
The metabolic events that often occur with everolimus
treatment – namely hypercholesterolaemia, hypergly-
caemia, hypophosphataemia, hypertriglyceridaemia, ele-
vated lactate dehydrogenase and hyperuricaemia – are
shown in Table 2 [19]. Abnormal laboratory values can
usually be managed routinely without treatment inter-
ruption. Intervention is recommended at grade 3 sever-
ity, with the nature of the intervention dependent on the
specific metabolic abnormality. It is important to bear in
mind that hypercholesterolaemia can increase the risk of
cardiovascular events and that hypertriglyceridaemia at
levels of ≥1,000 mg/dL can cause life-threatening
pancreatitis.
With regard to practical management, fasting blood
glucose and lipid profiles should be assessed before
starting everolimus and then monitored periodically (e.g.
every 6–8 weeks) during treatment. Patients with
diabetes require careful monitoring – and potential
modification – of their antihyperglycaemic medications.
In particular, metformin should be avoided in diabetic
patients with renal impairment (creatinine clearance
<30 mL/min/1.73 m2) and in patients with lactic acidosis
[53]. Statins and fibrates are recommended for lowering
total cholesterol and triglycerides, respectively, along
with lifestyle and nutritional changes. Consideration
should be given to the use of lipid regulating drugs since
some may not be licensed for use in children.
Haematological toxicity
Bone marrow suppression is a common toxicity associ-
ated with mTOR inhibitors. Grade 1 effects do not re-
quire any interruption of treatment. Thrombocytopenia
requires intervention at grade 2 and neutropenia at
grade 3. Thrombocytopenia and neutropenia are rarely
associated with clinically significant bleeding or infec-
tion, and hence do not typically necessitate platelet
transfusion or growth factor support [54]. Microcytosis
and hypochromia have also been reported in patients
with TSC treated with mTOR inhibitors; generally these
effects are self-limiting [18].
In cases of grade 3 toxicity, interruption of treatment
with everolimus is required, with a lowering of the dose
upon resumption. Everolimus should be discontinued in
any cases of life-threatening toxicity.
Renal AEs and proteinuria
Renal tubular abnormalities have been observed in pa-
tients treated with sirolimus [54], and hence physicians
should be vigilant when initiating everolimus, particularly
in patients with TSC with significant renal involvement.
Renal function should be assessed before starting everoli-
mus treatment and periodically thereafter (Fig. 1), which
should include assessment of urinary protein (e.g. urine
protein:creatinine ratio). Although AEs such as protein-
uria or an increased degree of proteinuria may be com-
mon, they are generally intermittent and should not
trigger treatment cessation. Angiotensin-converting en-
zyme (ACE) inhibitors and angiotensin receptor blockers
can be used to ameliorate microalbuminuria or protein-
uria when necessary. Cessation of everolimus should be
considered if there is progressively increasing proteinuria
to >1 g/day, especially if >3 g/day or if associated with per-
ipheral oedema. Similarly if GFR progressively declines to
<30 mL/min, cessation should be considered, although
this may be due to the underlying pathophysiology of TSC
rather than everolimus.
Additional patient considerations
Drug interactions
Everolimus is a substrate of cytochrome P450 3A4
(CYP3A4), and of the moderate inhibitor of P-
glycoprotein (P-gp). Hence, blood levels of everolimus
may be affected by products that inhibit or induce
CYP3A4 and/or P-gp. Specifically, CYP3A4 and P-gp in-
hibitors increase everolimus concentration and inducers
decrease everolimus concentration. Many patients with
TSC take antiepileptic medications that are CYP3A4
and/or P-gp inducers, which may decrease everolimus
concentrations. Indeed, in EXIST-2, mean trough blood
concentrations of everolimus were 4–8 ng/mL in pa-
tients taking enzyme-inducing drugs (mainly carbamaze-
pine), compared with 8.4–12.3 ng/mL in those who were
not [31].
Table 4 provides a list of inhibitors and inducers, and
recommendations for co-administration with everolimus
[19]. Potent inhibitors of CYP3A4 and/or P-gp are con-
traindicated with everolimus treatment; moderate inhibi-
tors should be used with caution, when unavoidable. If
co-administration of a CYP3A4 inducer (e.g. carbamaze-
pine) is required in patients treated for AML, the evero-
limus dose may need to be increased up to 20 mg/day.
Similarly, patients treated for SEGA may require an in-
creased everolimus dose to achieve the same exposure
as patients not taking potent inducers. Dosing should be
titrated to attain trough concentrations of 5–15 ng/mL.
If concentrations fall below 5 ng/mL, the daily dose may
be increased by 2.5 mg every 2 weeks, checking the
trough level and assessing tolerability before increasing
the dose. Patients should be advised not to use St John’s
Wort (a CYP3A4 inducer) or drink grapefruit juice (a
moderate CYP3A4/P-gp inhibitor) during treatment
with everolimus [19].
Patients taking concomitant ACE inhibitors may be at
increased risk of angioedema, although the evidence is
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not conclusive, and is seldom seen in practice [19]. Im-
paired wound healing is a class effect of rapamycin de-
rivatives, including everolimus; caution should therefore
be exercised with the use of everolimus in the peri-
surgical period [19], and treatment should be stopped
7–14 days prior to major invasive surgery procedures.
The treatment may be restarted after the surgical site is
completely healed [54].
Special populations
No dose adjustment is required in elderly patients (aged
≥65 years) who are otherwise fit, or in patients with
renal impairment [19]. In patients with renal AML and
hepatic impairment, the dose should be adjusted based
on Child–Pugh class [19, 55]. Everolimus dosing should
also be adjusted in adult patients with SEGA and hepatic
impairment [19, 55]. Everolimus is not recommended
for patients <18 years of age with SEGA and hepatic im-
pairment [19]. Calculation of Child-Pugh status and rec-
ommended everolimus dosing according to this status is
shown in Table 5. Everolimus whole blood trough con-
centrations should be assessed around 2 weeks after any
change in Child–Pugh status [19].
Monitoring blood levels of everolimus
In patients treated for SEGA, therapeutic drug monitor-
ing of everolimus blood concentrations is a requirement,
using a validated assay [19]. In patients aged <3 years of
Table 4 Drug interactions of note with everolimus [19]
Drug type Recommendation
Potent CYP3A4 and/or P-gp inhibitors
Ketoconazole, itraconazole, posaconazole, voriconazole telithromycin,
clarithromycin, nefazodone, ritonavir, atazanavir, saquinavir, darunavir,
indinavir, nelfinavir
Concomitant treatment of everolimus and potent inhibitors is not
recommended.
Moderate CYP3A4 and/or P-gp inhibitors
Erythromycin, imatinib, verapamil, ciclosporin oral, fluconazole
diltiazem, dronedarone, amprenavir, fosamprenavir
Use caution when co-administration of moderate CYP3A4
inhibitors or P-gp inhibitors cannot be avoided.
For patients with AML:
If patients require co-administration of a moderate CYP3A4 or P-gp inhibitor,
dose reduction to 5 mg or 2.5 mg daily may be considered. However, there
are no clinical data to guide this dose adjustment. Due to between-subject
variability, the recommended dose adjustments may not be optimal in all
individuals; therefore, close monitoring of adverse events is recommended.
If the moderate inhibitor is discontinued, consider a washout period of at
least 2–3 days before the everolimus dose is returned to the dose used prior
to initiation of the co-administration.
For patients with SEGA:
If patients require co-administration of a moderate CYP3A4 or P-pg inhibitor,
dose reduction by approximately 50% may be considered. Further dose
reduction may be required to manage adverse reactions. Trough
concentrations should be assessed approximately 2 weeks after the addition
of the CYP3A4/P-gp inhibitor; if this inhibitor is discontinued a 2–3 washout
period should be considered before everolimus reinitiation. Everolimus
trough concentrations should be assessed approximately 2 weeks after any
change in dose.
Potent and moderate CYP3A4 inducers
Rifampicin, dexamethasone, antiepileptic agents (e.g. carbamazepine,
phenobarbital, phenytoin), efavirenz, nevirapine
Avoid the use of concomitant potent CYP3A4 inducers.
For patients with AML:
If patients require co-administration of a potent CYP3A4 inducer, an
everolimus dose increase from 10 mg/day up to 20 mg/day should be
considered, using 5 mg increments or less applied on Days 4 and 8
following start of the inducer. This dose of everolimus is predicted to adjust
the AUC to the range observed without inducers. However, there are no
clinical data to support this dose adjustment. If treatment with the inducer
is discontinued, consider a washout period of at least 3–5 days (reasonable
time for significant enzyme de-induction) before the everolimus dose is
returned to the dose used prior to initiation of the co-administration
For patients with SEGA:
Patients receiving concomitant potent CYP3A4 inducers may require an
increased everolimus dose to achieve the same exposure as patients not
taking inducers. Dosing should be titrated to attain trough concentrations
of 5–15 ng/mL; daily dose may be increased by 2.5 every 2 weeks if values
are below this, checking the tolerability and trough levels before increasing.
If the inhibitor is discontinued a 2–3 washout period should be considered
before everolimus reinitiation. Everolimus trough concentrations should be
assessed approximately 2 weeks after any change in dose.
CYP3A4 inducer
St John’s Wort (Hypericum perforatum)
Preparations containing St John’s Wort should not be used during treatment
with everolimus
AUC area under the curve, CYP3A4 cytochrome P450 3A4, P-gp P-glycoprotein
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age, trough blood concentrations should be assessed
≥1 week after commencing treatment; for patients aged
≥3 years this should be done at around 2 weeks after
commencing treatment. Once a stable dose is attained,
trough concentrations should be monitored every 3–6
months in patients with changing BSA or every 6–12
months in patients with stable BSA, for the duration of
treatment.
In patients treated for renal AML associated with
TSC, therapeutic drug-monitoring of everolimus blood
concentrations is an option that should be considered,
using a validated assay [19]. Although the therapeutic
range of everolimus has not yet been defined, the blood
levels achieved with any particular dose varies between
individuals; trough concentrations in EXIST-2 ranged
from 7.63 to 9.37 ng/mL with large inter-individual vari-
ability [20]. A subsequent pharmacokinetic/pharmacody-
namic analysis found that trough levels ranged from
4.57 to 13.10 ng/mL for patients receiving either 5 mg
or 10 mg everolimus [31]. In an open-label extension
of EXIST-1, the median dose intensity per day was
5.9 mg/m2 with a range of 1.0–13.7 [23]. Therefore,
monitoring may be useful after initiation or a change
of everolimus dose/pharmaceutical form. Monitoring
should also be considered when CYP3A4 inducers or
inhibitors are prescribed, or in cases in which there is a
change in hepatic status (e.g. Child–Pugh status; Table 5)
[19]. When performing blood tests, consider using EMLA
cream, a local anaesthetic cream, or a freeze spray to min-
imise discomfort at the site of injection.
Fertility
An important consideration of treatment with everoli-
mus is fertility and how treatment may affect the ability
of the patients to conceive. According to the everolimus
Summary of Product Characteristics, women of child-
bearing potential are advised to use a highly effective
method of contraception for the duration of treat-
ment with everolimus and for up to 8 weeks after the
cessation of treatment [19]. It is the opinion of the
authors that women should cease everolimus ≥2 weeks
before stopping contraception — men may be allowed
to continue everolimus while attempting to father
children; however, if unsuccessful a discussion may be
needed about treatment cessation. Additionally, it
may be prudent for patients to have eggs or sperm
stored if they wish to have children after treatment
has finished.
Conclusions
Although everolimus-related AEs are fairly common
in patients with TSC they are often minor and usually
transient. More serious or recurrent AEs can often be
managed through dose adjustment or temporary ces-
sation of therapy. It is important to recognise, how-
ever, that the careful management of AEs means that
patients can continue on therapy for longer in order
to maximise benefit. Indeed, randomised studies of
everolimus in patients with TSC have shown that des-
pite the AEs that can occur, overall the benefits out-
weigh the risks. In the EXIST-2 trial of TSC patients
with AML, 5% (3 of 79) of everolimus-treated pa-
tients discontinued due to AEs, whereas 42% (33 of
79) responded [20]. In the EXIST-1 trial of TSC pa-
tients with SEGA, no everolimus-treated patients dis-
continued due to AEs, whereas 35% (27 of 78)
responded to treatment [21]. Additionally, expanded-
access trials in real-world patients with AML or
SEGA support the conclusion that everolimus has a
manageable safety profile [56, 57].
Table 5 Calculating Child–Pugh status and everolimus dosage recommendations [19, 55]
Factor 1 point 2 points 3 points
Total bilirubin (μmol/L) <34 34–50 >50
Serum albumin (g/L) >35 28–35 <28
PT INR <1.7 1.71–2.30 >2.30
Ascites None Mild to moderate Severe/refractory
Hepatic encephalopathy None Grade I–II (or suppressed with medication) Grade III–IV (or refractory)
Child–Pugh class Class A Class B Class C
Total points 5–6 7–9 10–15
Recommendation in patients
with AML
The recommended dose is
7.5 mg daily
The recommended dose is
5 mg daily
Everolimus is only recommended if
the desired benefit outweighs the
risk; a dose of 2.5 mg daily must
not be exceeded
Recommendation in patients
with SEGA
75% of the recommended starting
dose, calculation based on BSA
(rounded to the nearest strength)
25% of the recommended starting
dose, calculation based on BSA
(rounded to the nearest strength)
Everolimus is not recommended
PT INR prothrombin time and international normalized ratio
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The active management of TSC is important when
prescribing everolimus. Physicians should anticipate AEs
such as rash and stomatitis, and take appropriate mea-
sures to prevent them worsening for those affected. Fig-
ure 1 shows a protocol that may prove useful to
physicians throughout the management of patients with
TSC.
Physicians must be prepared to provide early educa-
tion to the patient (or carers/parents in the case of
paediatric patients) to aid this management, and in
the case of patients with learning difficulties must
consider additional strategies to deal with AEs
(Table 6). In addition to a list of items to consider
prior to the initiation of treatment with everolimus
dosing as well as monitoring requirements are also
important. As TSC is treated by a number of special-
ists such as nephrologists, neurologists, paediatricians
and geneticists, it is important that the multi-organ
effects of the disease and AEs are considered in any
management programme.
Continued surveillance is also required for possible
longer-term concerns, such as suppression of fertility,
proteinuria and hypophosphataemia, because patients
with TSC may need indefinite mTOR inhibition due to
the fact that tumours tend to regrow upon discontinu-
ation [1]. As with other AEs, these longer-term concerns
require active monitoring and management to ensure
that patients can continue to receive the benefit of
everolimus therapy. Initiatives such as TOSCA (Tuber-
Ous SClerosis registry to increase disease Awareness)
are underway that aim to provide long-term data on the
natural history and treatment of TSC [58], which will no
doubt prove useful for the development of future strat-
egies for AE management.
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